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Abstract
A substantial proportion of HIV-1-infected individuals are intravenous drug users (IVDUs) who abuse opiates. Opioids induce a number
of immunomodulatory effects that may directly influence HIV-1 disease progression. In the present report, we have investigated the effect
of opioids on the expression of the major HIV-1 coreceptors CXCR4 and CCR5. For these studies we have focused on opiates which are
ligands for the -opioid receptor. Our results show that DAMGO, a selective -opioid agonist, increases CXCR4 and CCR5 expression in
both CD3 lymphoblasts and CD14 monocytes three- to fivefold. Furthermore, DAMGO-induced elevation of HIV-1 coreceptor
expression translates into enhanced replication of both X4 and R5 viral strains of HIV-1. We have confirmed the role of the -opioid
receptor based on the ability of a -opioid receptor-selective antagonist to block the effects of DAMGO. We have also found that morphine
enhances CXCR4 and CCR5 expression and subsequently increases both X4 and R5 HIV-1 infection. We suggest that the capacity of
-opioids to increase HIV-1 coreceptor expression and replication may promote viral binding, trafficking of HIV-1-infected cells, and
enhanced disease progression.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Intravenous drug users (IVDUs) comprise over 30% of
the HIV-1-infected population, and many of these individ-
uals abuse opiates (Donahoe and Vlahov, 1998). The opioid
receptors are G-protein-coupled, seven-transmembrane re-
ceptors that have been cloned and subsequently grouped
into three classes, designated , , and  (Chen et al., 1993;
Kieffer et al., 1992; Li et al., 1993). The -opioid receptor
class is associated with the analgesic properties of mor-
phine, based on pharmacological data as well as the obser-
vation that morphine-induced analgesia is absent in -opi-
oid receptor knockout mice (Matthes et al., 1996).
Morphine appears to be the most active metabolite of her-
oin, and therefore, the effects of morphine on the immune
system are important in understanding the ramifications of
heroin abuse. The affinity of morphine for the -opioid
receptor is in the range of 10–20 nM, and during heroin
addiction IVDUs can reach levels of up to 2 g per day
(Jessop and Taplits, 1991). Patients receiving morphine as
therapy for chronic pain, or individuals abusing heroin, can
achieve plasma opioid levels of 1 g/ml or more (Mather
and Denson, 1992; Neumann et al., 1982).
Opioid receptors are expressed in the central nervous
system (CNS) and on cells of the immune system. Macro-
phages and T-lymphocytes have been shown to express
mRNA for opioid receptors, and binding analysis has re-
vealed surface expression of opioid receptors on these cells
(Chuang et al., 1994, 1995; Wick et al., 1996; Wybran et al.,
1979). Opioids are known to have several immunomodula-
tory activities, including inhibition of antibody responses
(Bussiere et al., 1993; Wybran et al., 1979), induction of
chemotaxis in mononuclear cells (Ruff et al., 1985), altered
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macrophage functions (Rojavin et al., 1993; Szabo et al.,
1993), and modulation of cytokine production (Chao et al.,
1992; Chuang et al., 1993b; Peterson et al., 1987). Opioid
use is also associated with enhanced progression of several
bacterial and viral infections (Risdahl et al., 1998). Recent
in vitro evidence suggests that opioids may also play a role
in HIV-1 disease progression. Peterson et al. (1990) have
shown that morphine pretreatment of PBMCs, chronically
infected with HIV-1 and cocultured with PHA-stimulated
PBMCs, induced a three- to fourfold increase in HIV rep-
lication. More recently, Peterson et al., (1994) showed that
morphine treatment also increased HIV replication in fetal
brain cells cocultured with a chronically infected monocytic
cell line. The basis for the opioid-mediated increase in HIV
susceptibility remains uncertain; however, our laboratory
has recently reported that -opioid administration induces a
significant increase in CC-chemokine receptor (CCR)-2 ex-
pression in murine T cells (Zhang and Rogers, 2000). Based
on these results, our laboratory investigated whether -opi-
oids, including morphine, may elevate the expression of the
major HIV-1 coreceptors CXCR4 and CCR5 (Alkhatib et
al., 1996; Feng et al., 1996). Our data indicate that the
expression of the major HIV-1 coreceptors is elevated in
CD14 monocytes and CD3 lymphoblasts. Furthermore,
this increase in CXCR4 and CCR5 expression on the major
cellular targets for HIV-1 translates into enhanced replica-
tion of X4 and R5 HIV-1 viral strains.
Results
DAMGO-induced chemokine receptor expression
To investigate the effect of -opioid administration on
the expression of CXCR4 and CCR5, normal human PBMCs
were treated with the highly selective -opioid agonist
DAMGO, and chemokine receptor expression was assessed
by flow cytometry. PBMCs were first gated for high forward
scatter to focus on the monocyte and lymphoblast popula-
tions. Our results showed that CXCR4 and CCR5 expres-
sion was enhanced in a dose-dependent manner in PBMCs
treated with DAMGO (Fig. 1). It should be noted that we
observed that basal expression of CXCR4 by nontreated
lymphoblasts was typically lower than in the total lympho-
cyte population, and basal levels can vary as much as
fivefold among donors. The induction of CCR5 and CXCR4
by DAMGO was consistent among donors; however, the
level of increase varied from two- to sevenfold depending
on the basal levels of chemokine receptor expression by
donors. We found that DAMGO induced an elevation in
CXCR4 and CCR5 expression by 48 h, with a maximal
effect at 72 h (data not shown). The percentage of CXCR4-
positive cells (Fig. 1; closed circles) increased by two- to
fivefold with increasing concentrations of DAMGO up to
the maximal effect at 10 nM DAMGO. Cells positive for
CCR5 (Fig. 1; closed triangles) increased two- to fourfold
after DAMGO administration, with the maximal effect ob-
served at concentrations between 0.1 and 10 nM. These
concentrations are physiologically relevant since the bind-
ing affinity of DAMGO and morphine is in the nanomolar
range for the -opioid receptor.
DAMGO-induced chemokine receptor expression is
mediated by the -opioid receptor
Due to the broad expression of CXCR4 on most hema-
topoietic cells and the sparse expression of CCR5, we
wished to focus our studies on the primary target cells for
HIV-1 infection which include T-lymphocytes and mono-
cytes (Alkhatib et al., 1996; Bleul et al., 1997; Zaitseva et
al., 1997). To better define the effect of DAMGO on
CXCR4 and CCR5 expression in specific cell populations,
we utilized two-color flow cytometric analysis to examine
CXCR4 expression on CD3 T-lymphocytes and CD14
monocytes. A representative dot plot (Fig. 2) of CD14 and
CCR5 expression in the high forward scatter gated popula-
tion shows that 8.1% of the cells were double-positive
without treatment (Fig. 2A). After treatment with DAMGO
for 72 h, the CD14 CCR5 population increased to 21.6%
(Fig. 2B). The induction of CCR5 expression by DAMGO
in the CD14 CCR5 population was blocked by a 30-min
pretreatment with 1 M CTAP, a -selective antagonist
(Fig. 2D). Based on two-color analysis, we found that
DAMGO significantly increased both CXCR4 and CCR5
expression in CD14 monocytes (Fig. 3A and B). Pretreat-
ment with the highly selective -opioid receptor antagonist
CTAP completely blocked the DAMGO-induced increase
of both CXCR4 and CCR5 expression. Our results showed
that CXCR4 expression was elevated twofold in CD14
monocytes treated with DAMGO (Fig. 3A). Similarly, the
administration of DAMGO also increased CCR5 expression
Fig. 1. The administration of DAMGO increases CXCR4 and CCR5
expression in monocytes and lymphoblasts. PBMCs were incubated over-
night and then incubated with medium alone or the -selective opioid
agonist DAMGO was added at the designated concentrations. After 72 h,
PBMCs were harvested and analyzed for expression of CXCR4 (filled
circles) or CCR5 (filled triangles) after gating for monocyte and lympho-
blast populations in a single gate for high forward scatter. Data are repre-
sentative of three experiments. Data are shown as the percentage of posi-
tive cells.
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twofold in CD14 monocytes (Fig. 3B). Additional studies
confirmed that the maximal elevation of CCR5 and CXCR4
was achieved at a concentration of 10 nM DAMGO (data
not shown and Fig. 1).
We also carried out an analysis of CD3 T-lymphocytes,
and our results showed that DAMGO treatment induced a
fourfold increase in CCR5 expression by CD3 T-lympho-
blasts (Fig. 3C and D). In contrast, levels of CCR5 ex-
pressed by nonlymphoblast (resting) CD3 T cells were not
significantly altered by DAMGO administration (Fig. 3C).
Not surprisingly, the expression of CCR5 by nonblast cells
was very low, since most of these cells are nonactivated T
cells which express low levels of CCR5 (Sallusto et al.,
1999). Moreover, the increase in CCR5 expression after
DAMGO administration was also blocked by pretreatment
with the -specific antagonist CTAP (Fig. 3D). Not surpris-
ingly, we found that CXCR4 expression in the CD3 non-
lymphoblast population was not altered after DAMGO ad-
ministration. In contrast, DAMGO induced a twofold
increase in CXCR4 expression in the CD3 lymphoblast
population (data not shown). The results in our study
showed donor variability in the basal levels of chemokine
receptor expression. However, most donors fell within a
range of two- to fivefold increase in chemokine receptor
expression with DAMGO administration.
DAMGO does not alter CCR1 expression
We extended our study to determine whether DAMGO
administration induced the expression of CCR1, since this
receptor is also expressed on both monocytes and T cells.
While CCR1 is widely expressed on lymphocytes and
monocytes (Su et al., 1996), it does not possess coreceptor
activity for HIV-1 (Hill et al., 1997, Rucker et al., 1997).
Cells were treated with 10 nM DAMGO, and the expression
of CCR1 on CD14 monocytes and CD3 lymphoblasts
was determined by flow cytometric analysis. Our results
showed that DAMGO administration did not induce a de-
tectable change in CCR1 expression for either CD14 or
CD3 cells (data not shown). Our data show that DAMGO
administration induces CXCR4 and CCR5 expression, but
fails to alter the expression of CCR1.
HIV-1 p24 levels are enhanced after DAMGO
pretreatment
We tested the possibility that by enhancing HIV-1 core-
ceptor expression DAMGO may increase the susceptibility
to HIV-1 infection. PBMCs were treated with 10 nM
DAMGO for 72 h to permit maximal coreceptor expression
and then infected with either HIV-1IIIB (X4 strain) or HIV-
1JRFL (R5 strain) for 2 h to permit viral binding. The cells
were then washed to remove unbound virus and incubated
for an additional 72 h, and supernatants were collected to
assess viral replication by HIV-1 p24 antigen production.
Our results (Fig. 4A) showed that X4 HIV-1 replication was
increased twofold in DAMGO-pretreated cells, and this
increase was completely reversed in DAMGO-treated cells
by CTAP (Fig. 4A). Moreover, susceptibility to R5 HIV-1
infection was also significantly increased in DAMGO-
Fig. 3. The administration of DAMGO increases CXCR4 and CCR5
expression in CD14 monocytes, and CD3 lymphoblasts, after 72 h.
Cells expressing the monocyte marker CD14 and either CXCR4 (A) or
CCR5 (B) were determined following treatment with medium alone (solid
bars), 10 nM DAMGO (hatched bars), 1 M CTAP (hatched bars), or 1
M CTAP for 30 min, followed by 10 nM DAMGO (crosshatched bars)
for 72 h. Alternatively, CD3 cells were initially gated into nonblast (C) or
blast populations (D) by forward and side scatter and analyzed for expres-
sion of CCR5. Data are shown as the mean (SD) of triplicate determi-
nations of percentage double-positive cells and are representative of five
experiments. *P  0.05.
Fig. 2. Treatment with DAMGO increases CCR5 expression in CD14
monocytes after 72 h. A representative dot-plot for double color flow
cytometric analysis is depicted (7500 cells counted). Nontreated PBMCs
(A), 10 nM DAMGO (B), 1 M CTAP (C), and 1 M CTAP for 30 min
followed by 10 nM DAMGO treatment (D) were analyzed for expression
of CD14 and CCR5. Data are representative of triplicate determinations
from one of five experiments.
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treated cells. Again, this effect was reversed by pretreatment
with CTAP (Fig. 4B). The data in Fig. 4 suggest that the
DAMGO-induced elevation in the major HIV-1 coreceptors
CXCR4 and CCR5 is coincident with enhanced HIV-1
replication. The effect of DAMGO on HIV-1 susceptibility
was consistent and reproducible in that we observed a two-
fold or greater increase in p24 levels in a total of 11 of 13
independent experiments, carried out with six donors. Ad-
ditional experiments showed that levels of HIV-1 p24 re-
mained elevated in the DAMGO-treated cells through at
least 120 h (data not shown).
HIV-1 LTR levels are enhanced after DAMGO
pretreatment
To further determine whether the DAMGO-induced el-
evation of HIV-1 coreceptor expression was linked to the
elevation of HIV-1 replication by DAMGO, we also per-
formed analysis of HIV-1 long-terminal repeat (LTR) as an
early indication of viral replication. Since the presence of
HIV-1 LTR is an early indication of acute infection, we
measured the production of LTR cDNA in PBMCs 4 h after
exposure to viral infection with either X4 or R5 viral strains.
Using PCR analysis, we found that DAMGO administration
72 h prior to infection elevated both HIV-1 X4 and R5 LTR
cDNA synthesis in PBMCs (Fig. 5). Pretreatment with
CTAP was able to block the DAMGO-induced elevation in
HIV-1 LTR expression, suggesting that the effect was
-opioid receptor mediated. These data suggest that
DAMGO alters an early event in viral replication, and this
leads to increased LTR transcription and viral replication.
This is consistent with the capacity of DAMGO to induce an
increase in coreceptor expression and accumulation of p24
in culture supernatants. The elevation of HIV-1 LTR was
significantly more robust than the effect of DAMGO on
HIV-1 p24 levels. The difference in the duration of HIV-1
infection (4 h for HIV-1 LTR and 72 h for HIV-1 p24) may
account for the difference in the apparent effect of DAMGO
on HIV-1 replication. During the 72-h infection period,
differences in the susceptibility of the cells to the infection
would be expected to “wash-out” as each cell is eventually
infected by the virus. After successful viral binding and
internalization, the virus would be expected to replicate at a
similar rate in both the DAMGO-treated and the nontreated
cell cultures, and this may allow non-DAMGO-treated cells
Fig. 5. DAMGO elevates PBMC susceptibility to HIV-1 infection as
measured by the accumulation of cDNA HIV-1 LTR. PBMCs were treated
with medium only, CTAP 106 M, DAMGO 108 M, or 106 M CTAP for
30 min prior to 108 M DAMGO for 72 h. Cells were then infected with
either the X4 strain HIV-1IIIB (A) or the R5 strain HIV-1JRFL (B). After 4 h
of infection, DNA was extracted and analyzed for LTR and -actin ex-
pression by PCR. Data are representative of three experiments.
Fig. 4. Treatment of PBMCs for 72 h with DAMGO increases suscepti-
bility to HIV-1 infection as measured by the accumulation of HIV-1 p24
antigen. Cells were treated with medium only (closed bars), 10 nM
DAMGO (hatched bars), 1 M CTAP (hatched bars), or 1 M CTAP for
30 min prior to 10 nM DAMGO (crosshatched bars) for 72 h. Cells were
then infected with either the X4 strain HIV-1IIIB (A) or the R5 strain
HIV-1JRFL (B). After 72 h of infection, supernatants were analyzed for
HIV-1 p24 by ELISA. Triplicate cultures were analyzed, and the results are
presented as the mean (SD) of triplicate determinations. Data are repre-
sentative of five experiments. *P  0.05.
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to “catch up” to the level of viral replication of DAMGO-
treated cells.
Morphine augments HIV-1 p24 levels
We wished to extend our studies to determine the capac-
ity of morphine to alter HIV susceptibility, since this opioid
agonist is a natural metabolic product of heroin. Morphine
primarily interacts with the -opioid receptor; however, this
opioid is less selective for the -opioid receptor than
DAMGO. Our results (Fig. 6) show that pretreatment of
PBMCs for 72 h with morphine enhances both HIV-1IIIB
(Fig. 6A) and HIV-1JRFL (Fig. 6B) replication. Morphine
also enhances CXCR4 and CCR5 expression, although the
effect was much more variable among donors when com-
pared to the highly selective -opioid agonist DAMGO.
Our data indicate that CXCR4 expression in CD3 lympho-
blasts is elevated from a minimum of 28% to a maximum of
300%, while CCR5 expression in CD14 monocytes in-
creases by a minimum of 24% to a maximum of 300% after
10 nM morphine administration. The variability in corecep-
tor expression may at least partially explain the dissimilarity
between donors in the baseline HIV-1 p24 levels following
infection (compare untreated cells in Fig. 4B with those in
Fig. 6B). The data show that morphine increases HIV co-
receptor expression, and this is associated with an increase
in susceptibility to HIV infection.
Morphine and DAMGO enhance CXCR4 and CCR5
mRNA expression
To further determine the effect of opioids on HIV-1
coreceptor expression, we utilized the RNase protection
assay (RPA) to determine if -opioids had an effect on
HIV-1 coreceptors at the mRNA level. We found that both
DAMGO and morphine had a statistically significant effect
on CXCR4 and CCR5 mRNA expression in all donors
analyzed; however, STRL33, US28, CCR3, CCR8, GPR1,
V28, and CCR2b mRNA expression were not consistently
altered (Figs. 7 and 8). Quantitation of the mRNA levels by
phosphoimaging showed that following DAMGO adminis-
tration the level of the minor HIV coreceptor GPR15 was
occasionally increased (fewer than half of all donors). Ad-
ditionally, several other chemokine receptors were analyzed
by RPA including CCR1-5, CCR8, and CXCR1-4, and only
CCR5 and CXCR4 mRNA expression were consistently
elevated following DAMGO administration (Fig. 7 and data
not shown). The expression of both CXCR4 and CCR5
mRNA was increased by approximately twofold with
DAMGO administration in each donor analyzed (Fig. 7),
which is consistent with the increase in protein expression
observed for this -opioid (Fig. 3). Additional studies (Fig.
8) showed that morphine also induced an increase in
CXCR4 and CCR5 mRNA levels, and the increase was less
robust than with DAMGO administration, but the effect was
statistically significant. Taken together, our results show
Fig. 7. DAMGO administration increases CXCR4 and CCR5 mRNA
expression in adherent cells from the total PBMC population. PBMCs were
incubated overnight and then incubated with medium alone or DAMGO
was added at the designated concentrations. After 24 h, adherent and
nonadherent PBMCs were harvested and analyzed for the expression of
CXCR4 or CCR5. A representative RPA is shown along with graphical
representation of the samples in triplicate. Data are representative of three
experiments. Data are shown as the percentage of the L32 housekeeping
gene expression. Lane 1 (0 nM), lane 2 (10 nM) and lane 3 (0.1 nM).
Fig. 6. Morphine augments PBMC susceptibility to HIV-1 infection.
PBMCs were treated with medium only (open bars) or morphine at the
designated concentrations (solid bars) for 72 h. Cells were then infected
with either the X4 strain HIV-1IIIB (A) or the R5 strain HIV-1JRFL (B).
After 72 h of infection, supernatants were analyzed for HIV-1 p24 by
ELISA. Triplicate cultures were analyzed, and the results are presented as
the mean ( SD) of triplicate determinations. Data are representative of
three experiments. *P  0.01.
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that the induction of CXCR4 and CCR5 is due to effects that
appear to be primarily at the level of receptor transcription.
Discussion
Our findings provide a potential mechanism to explain
the reported elevation in HIV-1 replication following mor-
phine administration (Peterson et al., 1990, 1994). Our stud-
ies suggest that the -opioids, including morphine, induce a
significant increase in HIV coreceptor expression on both
CD3 T-lymphoblasts and CD14 monocytes. Our data
show, moreover, that the induction of coreceptor expression
is associated with an increase in both X4 and R5 viral
replication. Analysis of LTR reverse transcription, an early
event in HIV infection, further corroborates these results by
correlating the elevated coreceptor levels with an increase in
early HIV replication. Our results are consistent with pre-
vious studies showing that upregulation of CCR5 or
CXCR4 expression results in elevated HIV-1 replication
(Secchiero et al., 1999; Tuttle et al., 1998).
To evaluate the effect of opioid administration on HIV-1
susceptibility, we carried out our experiments without acti-
vating agents such as phytohemagglutinin (PHA) or IL-2.
Our analysis has shown that PHA itself significantly ele-
vates CCR5 and CXCR4 expression, and this would mask
any potential effect on coreceptor expression. Of course,
nonactivated cells are less susceptible to HIV-1 infection;
however, we were able to achieve consistent and reproduc-
ible levels of HIV-1 replication in nonactivated cells. Scales
et al. (2001), Shapiro et al. (1999), and Wetzel et al. (2002)
found that nonactivated PBMCs or subsets of the nonacti-
vated PBMC population could be readily infected with
HIV-1. Also, Chun et al. (1998) found that resting CD4
T-lymphocytes from HIV-1 individuals expressed HIV-
LTR in all patients analyzed.
Our results agree with recent studies which have shown
that morphine induces CCR5 expression in the CEMx174
lymphocyte cell line and enhances syncytia formation in
these cells after infection with simian immunodeficiency
virus (SIV) (Miyag et al., 2000). Chuang et al. (1993a)
previously found that rhesus monkeys dependent on mor-
phine have an elevated rate of SIV viral replication. This is
in contrast with studies showing that chronic morphine
administration may have a protective effect on SIV infec-
tion (Donahoe et al., 1993). These conflicting results are
likely due, in part, to the differences in the virulence of the
SIV strains utilized and the amount of morphine adminis-
tered. There are also conflicting results arising from epide-
miological studies following HIV-infected IVDUs. While
studies have shown that CD4 counts were decreased and
mortality rates were elevated in HIV-infected IVDUs com-
pared to HIV-infected non-IVDUs (DesJarlaid et al., 1987;
Rothenberg et al., 1986), more recent reports have sug-
gested that CD4 counts are not altered in HIV-infected
IVDUs as compared to those in HIV-infected non-IVDUs
(Galai et al., 1995).
The molecular basis for the induction of coreceptor ex-
pression by opioids may be related to the well-established
capacity of opioids to alter cytokine expression in immune
cells. For example, morphine has been reported to elevate
the production of IL-2 from rhesus monkey lymphocytes
(Chuang et al., 1993b). Recent studies have shown that IL-2
enhances the expression of both CCR5 and CXCR4 by
CD4 T cells and CD4 memory cells, respectively (Jour-
dan et al., 2000; Weissman et al., 2000). In contrast, mor-
phine treatment has been found to inhibit the production of
IFN- by activated lymphocytes (Peterson et al., 1987).
Interestingly, IFN- has been reported to increase the ex-
pression of CCR5 and CXCR4 in monocytes (Hariharan et
al., 1999; Lee et al., 1999); however, conflicting results have
been observed which suggest that CXCR4 expression is
reduced in PBMCs and the promonocytic cell line U937
following IFN- treatment (Shirazi and Pitha, 1998). Fi-
nally, at picomolar concentrations, morphine has also been
shown to stimulate the production of TGF- (Chao et al.,
1992). It appears that TGF- induces an increase in the
expression of both CCR5 and CXCR4 by dendritic cells
(Sato et al., 2000), a population of accessory cells which is
believed to be critical for the sequestering of HIV-1 in the
thymus and lymph nodes (Granelli-Piperno et al., 1998). It
is possible that the opioid-mediated modulation of IL-2,
IFN-, or TGF-, alone or in combination, may be respon-
sible for the induction of CCR5 and CXCR4 expression on
monocytes and T lymphoblasts. The morphine-induced
modulation of cytokine production can be dependent on
Fig. 8. Morphine administration increases CXCR4 and CCR5 mRNA
expression in adherent cells from the total PBMC population. PBMCs were
incubated overnight and then treated with medium alone or with morphine
at the designated concentrations. After 24 h, adherent and nonadherent
PBMCs were harvested and analyzed for the expression of CXCR4 or
CCR5. A representative RPA is shown along with graphical representation
of the samples in triplicate. Data are representative of three experiments
and are shown as the percentage of L32 expression.
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both the cell population and the activation state of the cell
(Chao et al., 1992; Peterson et al., 1987). This may account
for the results observed in our studies which show an in-
duction of chemokine receptors on CD3 lymphoblasts, but
not on the nonlymphoblast population. This creates a com-
plex environment, in which subtle factors may play a pro-
nounced role in controlling the competence of the immune
system.
Our laboratory proposes a model for the effects of
DAMGO on HIV-1 infection. Engagement of the -opioid
receptor by DAMGO administration triggers events such as
cytokine production which can enhance expression of
CXCR4 and CCR5, the major HIV-1 coreceptors. The ele-
vation of coreceptor expression in the population of CD3
T-lymphoblasts and CD14 monocytes enhances viral bind-
ing and fusion of HIV-1 to target cells. This occurs within
a relatively short period of time (72 h), allowing HIV-1 to
rapidly infect additional target cells. The enhanced expres-
sion of HIV-1 coreceptors by activated T-lymphocytes
could enhance HIV-1 fusion with cells in a replication
competent state, thus allowing for enhanced viral produc-
tion. Previous studies from our laboratory have shown that
DAMGO elevates the expression of MCP-1 (monocyte che-
moattractant protein-1), RANTES (regulated upon activa-
tion, T cells, expressed and secreted), and IP-10 (IFN--
inducible protein-10) by 48 h in PBMCs (Wetzel et al.,
2000). The induction of both CCR5 and RANTES (a CCR5
agonist) expression by DAMGO would enhance chemotaxis
to sites of HIV-1 infection (Wetzel et al., 2000). Overall, the
enhanced HIV-1 coreceptor expression by DAMGO, along
with the production of RANTES and viral chemotactic
proteins, may create an environment in which DAMGO
elevates viral binding and fusion to host cells and also
increases trafficking of target cells to sites of infection.
Materials and methods
Cell culture
PBMCs were obtained from whole blood of normal do-
nors and isolated by Ficoll–Paque Plus (Pharmacia Biotech,
Piscataway, NJ) density gradient centrifugation. Isolated
PBMCs were plated at a cell density of 3  106 cells/ml in
24-well tissue culture plates. Cell cultures were maintained
in RPMI 1640 medium (Life Technologies, Rockville, MD)
supplemented with 10% heat-inactivated (56°C, 30 min)
endotoxin-free FBS (Hyclone, Logan, UT), 10 g/ml gen-
tamicin (Life Technologies), and 1 mM L-glutamine (Life
Technologies). Cell cultures were maintained at 37°C, 5%
CO2.
Opioid agonist and antagonist treatment
PBMCs were treated with agonist [D-Ala2, N-Me-Phe4,
Gly-ol5] enkephalin (DAMGO; Multiple Peptide Systems,
San Diego, CA) or morphine at designated concentrations
for 72 h. PBMCs pretreated with an antagonist were treated
with (D-Phe-Cys-Try-D-Trp-Arg-Thr-Pen-Thr-NH2) CTAP
(Multiple Peptide Systems), at the indicated concentrations,
30 min prior to DAMGO administration.
Flow cytometry and antibodies
PBMCs were harvested using versene to remove both
adherent and nonadherent cells. PBMCs were washed with
Hank’s balanced salt solution (Life Technologies) with 2%
endotoxin-free FBS (Hyclone) (HF), and resuspended in 50
l HF. Goat serum (Sigma, St. Louis, MO) was added to
block nonspecific binding, and cultures were incubated at
4°C for 30 min. Cells were treated with primary antibody,
incubated at 4°C for 45 min, and washed, and secondary
conjugated antibody was added where necessary. Samples
were analyzed with a Coulter Epics XL flow cytometer
(Coulter Corp., Hialeah, FL). Primary antibodies were as
follows: PE-CXCR4 (12G5), PE-CCR5 (2D7), FITC-CD3
(UCHT1), or FITC-CD14 (M5E2) from PharMingen (San
Diego, CA) or Biotin-CCR1 (53504.111) from R&D Sys-
tems (Minneapolis, MN). Secondary antibody for Biotin-
CCR1 was PE-streptavidin (Sigma). CD3-positive cells
were gated by forward and side scatter into lymphoblast
(high forward scatter) and resting (low forward scatter)
populations for analysis of CCR5 and CXCR4 expression.
HIV-1 viral strains
The viral strains HIV-1IIIB (X4) and HIV-1JRFL (R5)
were obtained from the National Institute of Allergy and
Infectious Diseases AIDS Research and Reference Reagent
Program operated by ERC Bioservices Corp. (Rockville,
MD). Virus was purified by pelleting at 110,000 g for 90
min. This procedure produces stock virus between 106 and
107 syncytia-forming units per 0.1 milliliter. The 50% tissue
culture infectious dose (TCID50) for the R5 virus was de-
termined using PBMCs.
p24 ELISA
HIV-1 p24 analysis was performed on PBMCs infected
with either an R5 or X4 HIV-1 viral strain at a multiplicity
of infection (m.o.i.) of 0.1, and free virus was washed off
after 2 h. Supernatants were collected 72 h post-HIV-1
infection. Supernatants were analyzed for p24 by ELISA
using rabbit anti-HIV-1 p24 capture antibody and goat anti-
rabbit IgG peroxidase-labeled detector antibody. The cap-
ture anti-p24 antibodies were provided on precoated ELISA
plates from the AIDS Vaccine Program and the NCI-Fred-
erick Cancer Research and Development Center. After
washing, the capture p24 was detected by developing the
peroxidase activity using 3,3,5,5-tetramethylbenzidine
and H2O2, and color development was measured by spec-
trophotometric analysis at 450 nm. As expected, p24 levels
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were higher for the X4 viral strain HIV-1IIIB than the R5
viral strain HIV-1JRFL.
RNase protection assay (RPA)
The MultiProbe RNase Protection Assay System
(PharMingen) was utilized to determine mRNA expression
of HIV-1 coreceptors. PBMCs were treated as above and
mRNA was extracted from both adherent or nonadherent
populations by RNAzol B (Tel-Test, Friendswood, TX).
The RiboQuant probe, hCR8, encoding riboprobes for
STRL33, US28, V28, GPR1, GPR15, CCR2b, CCR3,
CCR5, CCR8, and CXCR4, was labeled with [-32P]UTP
and hybridized to 10 g mRNA. The hybridized probe was
digested with RNase, and the protected probes were purified
and resolved on a 5% denaturing polyacrylamide gel. The
gel was then dried and exposed to audioradiogram film to
visualize the probe and samples. The gel was analyzed via
a phosphoimaging screen and using the GS-525 phospho-
imager (Bio-Rad, Hercules, CA) to obtain relative values
that were normalized to the large ribosomal subunit L32.
The data are shown as a percentage relative to L32.
Polymerase chain reaction (PCR)
The following primers were utilized to determine both
HIV LTR and -actin DNA expression. The primers for
HIV LTR were 5-AGCCTCAATAAAGCTTGCCT-3 and
5-CCCCCTGGCCTTAACCGAAT-3. The HIV LTR
primers were made from a highly conserved region of the
LTR which is homologous with both of the viral strains
utilized in our experiments. The primers for -actin were
5-GTGGGGCGCCCCAGGCACCA-3 and 5-CTCCT-
TAATGTCACGCACGATTTC-3. PBMCs were treated
with opioids as stated above and infected with either an X4
or a R5 viral strain for 1 h and washed, and 4 h later DNA
was extracted using the QIAmp DNA Mini Kit (Qiagen,
Valencia, CA). The PCR reaction was set up as stated in the
PCR Core System II procedure (Promega, Madison, WI).
The PCR reactions were run for 35 cycles (LTR) or 25
cycles (-actin) in a GeneAmp PCR System 2400 Thermo-
cycler (Perkin–Elmer, Boston, MA). PCR samples were
then run on a 1.2% agarose gel, captured using the Kodak
Electrophoresis Documentation and Analysis System
(EDAS) 290 (Eastman Kodak, Rochester, NY), and ana-
lyzed using the Kodak 1D Image Analysis Software (East-
man Kodak).
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